Iguratimod is a methanesulfonanilide disease-modifying anti-rheumatic drug [1,3-4]. Evidence from a mouse colitis model shows an anti-inflammatory effect of iguratimod, partly via regulation of Th17/Treg cells [2], that suggest iguratimod as a novel therapeutic for the treatment of IBD.